mTOR inhibitors in cancer therapy

被引：259

作者：

Zaytseva, Yekaterina Y. ^{[1
]}

Valentino, Joseph D. ^{[1
,2
]}

Gulhati, Pat ^{[3
]}

Evers, B. Mark ^{[1
,2
]}

机构：

[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA

[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA

[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA

来源：

CANCER LETTERS | 2012年 / 319卷 / 01期

关键词：

mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;

D O I：

10.1016/j.canlet.2012.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 7

页数：7

共 50 条

[21] Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Kim, Hyera
Lee, Su Jin
Lee, In Kyoung
Min, Suejean C.
Sung, Hyun Hwan
Jeong, Byong Chang
Lee, Jeeyun
Park, Se Hoon
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
[22] The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
Ihlamur, Murat
Akgul, Busra
Zengin, Yagmur
Korkut, Senay Vural
Kelleci, Kubra
Abamor, Emrah Sefik
CURRENT MOLECULAR MEDICINE, 2024, 24 (04) : 478 - 494
[23] mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Zhilin
Tao, Tao
Li, Hongmei
Zhu, Xiao
CELL AND BIOSCIENCE, 2020, 10 (01):
[24] mTOR inhibitors in urinary bladder cancer
Pinto-Leite, R.
Arantes-Rodrigues, R.
Sousa, Nuno
Oliveira, P. A.
Santos, L.
TUMOR BIOLOGY, 2016, 37 (09) : 11541 - 11551
[25] mTOR Inhibitors in the Treatment of Breast Cancer
Vinayak, Shaveta
Carlson, Robert W.
ONCOLOGY-NEW YORK, 2013, 27 (01): : 38 - +
[26] Cancer and mTOR Inhibitors in Transplant Recipients
de Fijter, Johan W.
TRANSPLANTATION, 2018, 102 (02) : S60 - S70
[27] Will mTOR inhibitors make it as cancer drugs?
Sawyers, CL
CANCER CELL, 2003, 4 (05) : 343 - 348
[28] Safety of mTOR inhibitors in breast cancer
Studentova, Hana
Vitaskova, Denisa
Melichar, Bohuslav
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1075 - 1085
[29] Cancer and mTOR Inhibitors in Transplant Recipients
de Fijter, Johan W.
TRANSPLANTATION, 2017, 101 (01) : 45 - 55
[30] mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou
Tao Tao
Hongmei Li
Xiao Zhu
Cell & Bioscience, 10

← 1 2 3 4 5 →